PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817379/
https://www.ncbi.nlm.nih.gov/pubmed/20145726
http://dx.doi.org/10.1155/2010/207420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817379/
https://www.ncbi.nlm.nih.gov/pubmed/20145726
http://dx.doi.org/10.1155/2010/207420

Ejemplares similares